Table 1 Study patient characteristics

Age (median, range)

57 (45–81)

57 (39–78)

0.83

Histology

0.29

 High grade serous

11

(91.7%)

13

(100%)

 Adenocarcinoma

1

(8.3%)

0

(0.0%)

FIGO stage

0.85

 Stage III

6

(50.0%)

6

(46.2%)

 Stage IV

6

(50.0%)

7

(53.8%)

Tumor size (cm) (median, range)

7

(3–16)

7

(3–14)

0.83

Residual tumor

0.55

 Optimal surgery

9

(75.0%)

11

(84.6%)

 Suboptimal surgery

3

(25.0%)

2

(15.4%)

CA-125 KELIM

0.02

 Favorable KELIM

8

(66.7%)

13

(100%)

 Unfavorable KELIM

4

(33.3%)

0

(0.0%)

 NAC cycle (median, range)

5

(3–6)

5

(3–7)

0.15

 Use of BEV after IDS

5

(41.7%)

4

(30.8%)

0.57

 Use of PARPi after IDS

4

(33.3%)

10

(76.9%)

0.07

 HRD

3 (/6)

(50.0%)

8 (/8)

(100%)

0.02

 Germline BRCA 1/2 mutation

3 (/6)

(50.0%)

6 (/11)

(54.5%)

0.86